Premium
Multicenter Study on the Long‐Term (3‐Year) Efficacy of Lanthanum Carbonate in Dialysis Patients
Author(s) -
Ando Ryoichi,
Yama Satomi,
Ohnishi Tsuyoshi,
Iwamoto Shunsuke,
Kimura Hitoshi,
Chida Yoshiko,
Ishida Yuji,
Yamada Kouei,
Inagaki Yuichiro,
Takayama Masanobu,
Tachibana Ken,
Kikuchi Kan,
Inoue Atsushi,
Ohtsuka Masakazu
Publication year - 2014
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12206
Subject(s) - lanthanum carbonate , hyperphosphatemia , medicine , parathyroid hormone , dialysis , phosphate binder , guideline , multicenter study , gastroenterology , endocrinology , calcium , randomized controlled trial , pathology
We previously conducted a multicenter study enrolling 101 dialysis patients with hyperphosphatemia in which lanthanum carbonate ( LC ) was administered for 2 years. In this study, the administration has been continued for an additional year, and we have evaluated the long‐term (a total of 3 years) effects of LC . The average serum phosphorus ( P ) level was 6.05 mg/ dL at the start and decreased to 5.84 mg/ dL after 3 years, but no significant differences were observed at both points. The average serum corrected calcium ( C a) level significantly reduced after 3 years ( P < 0.001). As results of evaluating the achievement rates with the management target values of serum P , C a and intact parathyroid hormone ( PTH ) stated in the Japanese guideline, the achievement rates increased after 3 years. From these results, LC is considered to be a useful P binder that can be used for long‐term treatment of hyperphosphatemia, without causing a C a load.